WHAT IS CLAIMED IS:

1. Use of meropenem in the manufacture of a first medicament and use of vaborbactam in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combinatorial therapy to treat one or more bacterial infection in a subject, wherein the subject is immunocompromised, wherein the combinatorial therapy is to be administered to the subject in need thereof, wherein the subject achieves a maximum post baseline creatinine increase of <0.5 mg/dL, and wherein the bacterial infection is selected from the group consisting of *Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae species complex, Enterococcus faecium, Serratia marcescens, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia trachomatis, Mycoplasma pneumoniae, and Legionella pneumophila, Acinetobacter baumannii, Bartonella bacilliformis, Brucella species, Calymmatobacterium granulomatis, Campylobacter fetus, Francisella tularensis, Haemophilus ducreyi, Vibrio cholerae, and Yersinia pestis*.

2. The use of Claim 1, wherein the subject has a history of ongoing leukemia or lymphoma.

3. The use of Claim 1, wherein the subject has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy.

4. The use of Claim 1, wherein the subject is to receive immunosuppressive medications.

5. The use of Claim 1, wherein the subject is to receive bone marrow ablative chemotherapy.

6. The use of Claim 1, wherein the subject has neutropenia.

7. The use of Claim 1, wherein the subject is suffering from or has suffered from a malignancy.

8. Use of meropenem in the manufacture of a first medicament and use of vaborbactam in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combinatorial therapy to treat one or more bacterial infection in a subject, wherein the subject is suffering from or has suffered from a malignancy, and wherein the combinatorial therapy is to be administered to the subject in need thereof, wherein the subject achieves a maximum post baseline creatinine increase of <0.5 mg/dL, and wherein the bacterial infection is selected from the group consisting of *Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae species complex, Enterococcus faecium, Serratia marcescens, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia trachomatis, Mycoplasma pneumoniae, and Legionella pneumophila, Acinetobacter baumannii, Bartonella bacilliformis, Brucella species,*

Calymmatobacterium granulomatis, Campylobacter fetus, Francisella tularensis, Haemophilus ducreyi, Vibrio cholerae, and Yersinia pestis.

9. The use of Claim 7, wherein the malignancy is a hematological malignancy, and wherein the hematological malignancy is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, AIDS-related lymphoma, primary CNS lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, leukemia, multiple myeloma, myoproliferative neoplasms, and Sezary syndrome.

10. The use of Claim 7, wherein the subject is suffering from or has suffered from a solid tumor, and wherein the solid tumor is a sarcoma or carcinoma.

11. The use of Claim 1, wherein the subject has an absolute neutrophil count below about 1000 cells/mm^3.

12. The use of Claim 1, wherein the administration is oral, intravenous, intraperitoneal, intragastric, or intravascular administration.

13. The use of Claim 1, wherein the dose of the meropenem to be administered is between 1 mg and 5000 mg and the dose of the vaborbactam to be administered is between 1 mg and 5000mg.

14. The use of Claim 13, wherein the dose of meropenem is 10 mg to 3000 mg and the dose of vaborbactam is 10 mg to 3000 mg.

15. The use of Claim 13, wherein the dose of meropenem is 100 mg to 2000 mg and the dose of vaborbactam is 100 mg to 2000 mg.

16. The use of claim 1, wherein the meropenem and vaborbactam are to be administered in a weight ratio from 2:1 to 1:2.

17. The use of Claim 1, wherein the meropenem and the vaborbactam are to be administered from one to four times daily, and wherein the meropenem and vaborbactam are to be administered from 1 day to at least 4 weeks.

18. The use of claim 1, wherein the meropenem and vaborbactam are to be administered simultaneously.